Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding

Area of Science:

• Cardiology
• Clinical Medicine
• Pharmacology

Background:

• Bleeding complications in acute myocardial infarction (AMI) patients are linked to poorer long-term outcomes.
• Withholding antiplatelet therapy post-bleeding may increase recurrent cardiovascular events.

Purpose of the Study:

• To investigate the association between in-hospital bleeding and antiplatelet medication use after AMI.
• To determine the duration of antiplatelet therapy discontinuation following bleeding events in AMI patients.

Main Methods:

• Analysis of 2498 patients from the PREMIER registry, examining medication use at discharge, 1, 6, and 12 months post-AMI.
• Bleeding defined as non-CABG related TIMI major/minor bleeding or transfusion.
• Logistic regression used to assess the link between bleeding and medication adherence.

Main Results:

• 12% of AMI patients experienced in-hospital bleeding.
• Patients with bleeding were less likely to be discharged on aspirin or thienopyridines.
• Antiplatelet therapy use normalized by 1 year, with cardiology follow-up associated with higher adherence.

Conclusions:

• AMI patients with bleeding complications receive less antiplatelet therapy in the first six months post-discharge.
• Reassessing antiplatelet eligibility early after bleeding can mitigate long-term adverse outcomes.